Lumida
/CATX
⌘K
Perspective Therapeutics Inc

Perspective Therapeutics Inc

CATX
$2.81USD+1.44%+0.04 today

MARKET CAP

320.8M

P/E (TTM)

FWD P/E

DAY RANGE

$3 – $3

52W RANGE

$2
$6

AI Summary

Stalk
Sell NowHigh

CATX remains in a high-confidence Stage 4 decline, trading below all major moving averages with no active patterns to support a rally. Medium-term bearish structure is intact under a sequence of lower highs and lower lows, and short-term conditions show a lack of upside follow-through into declining EMAs. Execution should focus on selling into any relief rallies around the 9/21 EMA zone. A decisive close and hold above those EMAs would invalidate the bearish bias.

  • Completed PSV359 Phase1/2a dosing, enabling next pivotal trials.
  • Analyst consensus Buy with $11.50 target implies 248.5% upside.
  • Q2 net loss $26.8M strains cash runway amid revenue shortfall.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2023FY 2024FY 2025TREND
Sales, Adj.$1.4M$1.5M$884,000
YoY %+1.4%-39.2%
P / Sales74.9x141.3x229.6x
EV / Sales84.3x133.7x262.8x
Gross Profit, Adj.$1.4M$1.5M$884,000
YoY %+1.4%-39.2%
Margin %100.0%100.0%100.0%
EV / Gross Profit84.3x133.7x262.8x
EBITDA, Adj.$-40.0M$-64.5M$-110.3M
YoY %-61.4%-71.1%
Margin %-2786.3%-4435.4%-12478.8%
EV / EBITDA-3.0x-3.0x-2.1x
EBIT$-40.9M$-90.9M$-113.6M
YoY %-121.9%-25.0%
Margin %-2855.0%-6248.9%-12846.6%
EV / EBIT-3.0x-2.1x-2.0x
Net Income$-46.5M$-79.3M$-103.1M
YoY %-70.5%-30.1%
Net Margin-3243.2%-5452.5%-11665.3%
EPS (GAAP)-$1.74-$1.23-$1.40
YoY %+29.3%-13.8%